Could Medicure Inc Increase Even More? The Stock Just Had a Gap Up

 Could Medicure Inc Increase Even More? The Stock Just Had a Gap Up

The stock of Medicure Inc (CVE:MPH) gapped up by $0.16 today and has $8.53 target or 3.00% above today’s $8.28 share price. The 7 months technical chart setup indicates low risk for the $131.91M company. The gap was reported on Nov, 29 by Barchart.com. If the $8.53 price target is reached, the company will be worth $3.96M more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. About 9,413 shares traded hands. Medicure Inc (CVE:MPH) has risen 6.00% since October 30, 2016 and is uptrending. It has outperformed by 0.74% the S&P500.

More news for Medicure Inc (CVE:MPH) were recently published by: Midasletter.com, which released: “S&P/TSX Venture Composite Index Movers: GoldMoney Inc., Medicure Inc …” on February 02, 2016. Seekingalpha.com‘s article titled: “Undervalued And Underfollowed; Medicure Is My Favorite Pharma Small Cap” and published on February 17, 2016 is yet another important article.

Medicure Inc. is a pharmaceutical firm engaged in the research, clinical development and commercialization of human therapeutics. The company has a market cap of $131.91 million. The Firm operates in the biopharmaceutical industry segment. It has a 29.19 P/E ratio. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc.

MPH.V Company Profile

Medicure Inc. (Medicure), incorporated on February 23, 2000, is a pharmaceutical firm engaged in the research, clinical development and commercialization of human therapeutics. The Firm operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc. The Firm is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment